5273-96-1

Basic information

• Product Name: 2-cyano-3-[5-(2-nitrophenyl)furan-2-yl]-N-(2,4,6-trimethylphenyl)prop-2-enamide
• CAS NO: 5273-96-1
• Molecular Formula: C₁₂H₁₆O₃
• Molecular Weight: 401.4147
• Mol File: 5273-96-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 620.5°C at 760 mmHg
• Flash Point: 329°C
• Density: 1.295g/cm³
• Vapor Pressure: 2.55E-15mmHg at 25°C
• Refractive Index: 1.654
• CAS DataBase Reference: 2-cyano-3-[5-(2-nitrophenyl)furan-2-yl]-N-(2,4,6-trimethylphenyl)prop-2-enamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-cyano-3-[5-(2-nitrophenyl)furan-2-yl]-N-(2,4,6-trimethylphenyl)prop-2-enamide(5273-96-1)
• EPA Substance Registry System: 2-cyano-3-[5-(2-nitrophenyl)furan-2-yl]-N-(2,4,6-trimethylphenyl)prop-2-enamide(5273-96-1)

Safety Data

• Hazardous Substances Data: 5273-96-1(Hazardous Substances Data)

Upstream product

• 5273-94-9 1-(2,4,6-trimethoxyphenyl)-2-propene 
• 32977-06-3 1-(allyloxy)-3,5-dimethoxybenzene 
• 32977-07-4 2-allyl-3,5-dimethoxyphenol 
• 830-79-5 2,4,6-trimethoxybenzaldehyde 
• 1530-32-1 ethyltriphenylphosphonium bromide 
• 500-99-2 3,5-dimethoxyphenol 
• 834-93-5 1,3,5-trimethoxy-2-(1-hydroxypropyl)benzene 

Downstream Products

• 834-94-6 1-(2,4,6-trimethoxyphenyl)propan-1-one 
• 835-25-6 1-(2,4,6-trimethoxyphenyl)propan-2-one 

Relevant articles and documents

Synthesis, antiepileptic effects, and structure-activity relationships of α-asarone derivatives: In vitro and in vivo neuroprotective effect of selected derivatives

In the present study, we compared the antiepileptic effects of α-asarone derivatives to explore their structure-activity relationships using the PTZ-induced seizure model. Our research revealed that electron-donating methoxy groups in the 3,4,5-position on phenyl ring increased antiepileptic potency but the placement of other groups at different positions decreased activity. Besides, in allyl moiety, the optimal activity was reached with either an allyl or a 1-butenyl group in conjugation with the benzene ring. The compounds 5 and 19 exerted better neuroprotective effects against epilepsy in vitro (cell) and in vivo (mouse) models. This study provides valuable data for further exploration and application of these compounds as potential anti-seizure medicines.

An effective system to synthesize hypolipidemic active α-asarone and related methoxylated (E)-arylalkenes

Methoxylated (E)-arylalkenes (1a-1k) were prepared in two steps by an improved Grignard reaction comprising the reverse addition of alkylmagnesium bromide to benzaldehydes (2a-2k) in anhydrous ether and toluene into arylalkanols (3a-3k) in high yield, followed by dehydration with silica gel under microwave irradiation for 3-12 min, depending upon the substituents attached to the aromatic ring to afford hypolipidemic active α-asarone (1a) and related methoxylated (E)-arylalkenes (1b-1k).

Synthesis and hypolipidemic and antiplatelet activities of α-asarone isomers in humans (in vitro), mice (in vivo), and rats (in vivo)

A series of α-asarone isomers was synthesized and investigated for their hypolipidemic and antiplatelet activity. Considering the hypolipidemic activity in rats at a dose of 80 mg/kg/day, some isomers were more potent than clofibrate at 150 mg/kg. Compoun